E. Sachs, S. Sachs, J. D. Savioli, L. Zeledo?nzeledo?n, R. Rabinovich et al., Control of neglected tropical diseases. New Engl World Health Organization. Working to overcome the global impact of neglected tropical diseases Chagas' disease: an ecological appraisal with special emphasis on its insect vectors, J. Med. Annu. Rev. Entomol, vol.357, issue.26, pp.101-134, 1981.

A. C. Moore, J. A. Urbina, W. Souza, J. C. Rodrigues, and T. Y. Hargrove, Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches (6) ClinicalTrial.gov. Proof-of-concept study of E1224 to treat adult patients with Chagas disease Sterol biosynthesis pathway as target for antitrypanosomatid drugs, Evaluation and treatment of Chagas disease in the United States: a systematic review 642?502. (8) Lepesheva, G. I.; Villalta, F.; Waterman, M. R. Targeting Trypanosoma cruzi sterol 14?-demethylase (CYP51). Adv. Parasit, pp.55-68, 2007.

V. Furtak, Z. Wawrzak, F. Villalta, M. R. Waterman, C. K. Chen et al., Structural insights into inhibition of sterol 14?-demethylase in the human pathogen Trypanosoma cruzi Structural characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei bound to the antifungal drugs posaconazole and fluconazole. PLoS Neglect, 25582? 25590. (10), 2010.

K. K. Ang, J. H. Mckerrow, L. M. Podust, G. Lepesheva, and W. D. Nes, Trypanosoma cruzi CYP51 inhibitor derived from a Mycobacterium tuberculosis screen hit. PLoS Neglect, 2009.

F. Villalta and M. R. Waterman, CYP51: A major drug target in the cytochrome P450 superfamily, Lipids, vol.43, issue.14, pp.1117-1125, 2008.

A. Palamara, Synthesis and antifungal activity of a new series of 2-(1H- imidazol-1-yl)-1-phenylethanol derivatives, 334?342. (15) Orhan, I.; S? ener, 2012.
URL : https://hal.archives-ouvertes.fr/pasteur-00968658

I. C. Lennon and J. A. Ramsden, An efficient catalytic asymmetric route to 1-aryl-2-imidazol-1-yl-ethanols 110?112. (17) Maestro, version 9.2; Schro? dinger, LLC Molecular recognition of receptor size using a genetic algorithm with a description of desolvation, 18) Macromodel, version 9.2; Schro? dinger, pp.47-58, 1920.

R. Lepesheva, G. I. Jurima-romet, M. Crawford, K. Cyr, T. Inaba et al., Substrate preferences and catalytic parameters determined by structural characteristics of sterol 14?-demethylase (CYP51) from Leishmania infantum Terfenadine metabolism in human liver: in vitro inhibition by macrolide antibiotics and azole antifungals Effect of CYP3A inhibition on vesnarinone metabolism in humans, 849?857. (22)23) Rando, R. R. Mechanism-based enzyme inactivators, pp.63-506, 1994.